Roman R,¹ Colomer A,¹ Erill N,¹ Verdú M,² Ibáñez R,¹ Cordon-Cardo C,¹ Puig X.^1,2

¹BIOPAT. Biopatologia Molecular, Grup Assistència & ²HISTOPAT Laboratoris, Barcelona, Catalonia, Spain.

Background: Irinotecan (CPT-11) is currently used as first- or second-line treatment for colorectal cancer, either alone or in combination with 5-fluorouracil based regimens. UDP-glucuronosyltransferase 1A1 (UGT1A1) catalyzes the inactivation of SN-38, the active metabolite of irinotecan, through glucuronidation. UGT1A1*28, a polymorphic variant of this enzyme displaying an additional TA dinucleotide in the promoter TATA box, has been […]

Nadina Erill¹, Anna Colomer¹, Miquel Calvo², August Vidal³, Ruth Román^1, Montse Verdú³, Carlos Cordón-Cardó⁴, Xavier Puig^1,3.

¹BIOPAT, Grup Assistència, Statistics Department, ²Universitat de Barcelona, ³HISTOPAT Laboratoris, Barcelona, and ⁴Division of Molecular Pathology,  Memorial Sloan-Kettering Cancer Center,  New York.

Chromosome 18q allelic loss has been reported to have prognostic significance in stage II colorectal carcinoma. We have developed a fluorescent multiplex polymerase chain reaction assay to analyze five microsatellite markers (D18S55, D18S58, D18S61, D18S64 and D18S69) for allelic loss determination at the long […]

Anna Colomer¹, Nadina Erill¹, August Vidal², Miquel Calvo^3, Ruth Román¹, Montse Verdú^2, Carlos Cordon-Cardo⁴, Xavier Puig ^1,2.

¹BIOPAT, Grup Assistència, Barcelona; ²HISTOPAT Laboratoris, Barcelona; ³Statistics Department of the Universitat de Barcelona, Barcelona and ⁴Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

High-frequency microsatellite instability has been reported to be associated with good prognosis in colorectal adenocarcinoma. However, methods to assess microsatellite instability (MIN) are based on genetic assays, and are not ideally suited to […]